Pavan Cheruvu is listed as a director on 1 SEC Form D filing by 1 issuer in Dec 2025: Imbria Pharmaceuticals, Inc. (Boston, MA — biotechnology — 2025; $66.7M reported sold to 10 investors).
What this means One deal on file with the SEC, filed Dec 2025. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Alvin Shih (1 shared filing), Andrew Levin (1 shared filing), Charles Dunn (1 shared filing), Ken Horne (1 shared filing), Komal Joshi (1 shared filing) and 2 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Pavan. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — 1 court case matching the name listed in Key records below.
What this means 1 record came back, including 1 court case still open — open cases can take years and cost money. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 1 public filing for Pavan Cheruvu and found 1 difference: Offering amount changed between filings.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.